secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001193125-24-045464
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine appoints Pamela Stephenson as CCO; grants inducement equity award
-------------------------------------------------------------------------------

- Pamela Stephenson, MPH, named Chief Commercial Officer effective Feb 26, 2024.
- Stephenson has 25+ years biopharma experience, most recently CCO of Albireo (acquired by Ipsen).
- Inducement award: option to purchase 55,000 shares and RSU for 36,666 shares under Nasdaq Rule 5635(c)(4).
- Option vests 25% on first anniversary, then monthly; RSU vests in four equal annual installments.
- Company is clinical-stage biopharma focused on serious hematologic diseases (NASDAQ:IRON).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524045464/0001193125-24-045464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524045464/d794509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-045464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer